The benefits, costs and feasibility of a low incidence COVID-19 strategy.
The benefits, costs and feasibility of a low incidence COVID-19 strategy.
复制标题
DOI：
10.1016/j.lanepe.2021.100294
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Wilmes P
中科院分区：
文献类型：
--
作者：
Czypionka T;Iftekhar EN;Prainsack B;Priesemann V;Bauer S;Calero Valdez A;Cuschieri S;Glaab E;Grill E;Krutzinna J;Lionis C;Machado H;Martins C;Pavlakis GN;Perc M;Petelos E;Pickersgill M;Skupin A;Schernhammer E;Szczurek E;Tsiodras S;Willeit P;Wilmes P
于二零二一年夏季，欧洲各国政府在经历COVID-19疫情的第二波及第三波长时间爆发后，取消了大部分不良资产。大多数国家未能实现足够高的免疫接种率，以避免病毒死灰复燃。2021年秋冬季的公共卫生策略从重新引入NPI以降低发病率为目标的国家到接受高发病率水平的国家。然而，这种高发生率的策略几乎肯定会导致他们试图避免的后果：损害人民和经济的限制。在高发病率下，重要的大流行遏制措施“测试-跟踪-隔离-支持”变得低效。在这一点上，SARS-CoV-2的传播及其众多有害后果可能只能通过限制来控制。我们认为，所有欧洲国家都需要以协调一致的方式实施低发病率战略。这种努力只有建立在公开交流和信任的基础上，才能取得成功。
In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust.
登录
查看更多内容
影响因子：
8.3
作者：
Byun WS;Heo SW;Jo G;Kim JW;Kim S;Lee S;Park HE;Baek JH
通讯作者：
Baek JH
影响因子：
16.6
作者：
Contreras S;Dehning J;Loidolt M;Zierenberg J;Spitzner FP;Urrea-Quintero JH;Mohr SB;Wilczek M;Wibral M;Priesemann V
通讯作者：
Priesemann V
DOI：
10.15585/mmwr.mm7022e1
发表时间：
2021-06-04
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Barry V;Dasgupta S;Weller DL;Kriss JL;Cadwell BL;Rose C;Pingali C;Musial T;Sharpe JD;Flores SA;Greenlund KJ;Patel A;Stewart A;Qualters JR;Harris L;Barbour KE;Black CL
通讯作者：
Black CL
影响因子：
6.4
作者：
Ravens-Sieberer U;Kaman A;Erhart M;Devine J;Schlack R;Otto C
通讯作者：
Otto C
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK